Blog
RSS FeedPosted by Michael Wonder on 20 Oct 2024
Prostate cancer: significant additional benefit for PSMA diagnostics with gozetotide
15 October 2024 - Because of the direct link between diagnosis and therapy, the data from the early benefit assessment ...
Posted by Michael Wonder on 03 Sep 2024
Vadadustat for symptomatic anaemia due to chronic kidney disease: missed opportunity
2 September 2024 - In the two manufacturer studies, important patient-relevant outcomes were not recorded. ...
Posted by Michael Wonder on 03 Jul 2024
Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent
1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...
Posted by Michael Wonder on 02 Apr 2024
Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...
Posted by Michael Wonder on 04 Mar 2024
Tebentafusp in uveal melanoma: indication of a considerable additional benefit
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
Posted by Michael Wonder on 02 Mar 2024
Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
Posted by Michael Wonder on 09 Oct 2023
Multiple sclerosis: hardly any evidence for good patient care
4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...
Posted by Michael Wonder on 02 Sep 2023
Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients
1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...
Posted by Michael Wonder on 02 Aug 2023
Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies
1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies ...
Posted by Michael Wonder on 02 May 2023
Trastuzumab deruxtecan: benefits also in HER2 low breast cancer
2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable ...
Posted by Michael Wonder on 17 Apr 2023
Olaparib in metastatic prostate cancer: added benefit for certain patients
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 17 Jan 2023
Vutrisiran in hereditary transthyretin amyloidosis: hint of minor added benefit
17 January 2023 - Vutrisiran is approved for the treatment of patients with hereditary transthyretin amyloidosis with stage 1 or ...